MBRX Moleculin Biotech, Inc.

NASDAQ
$0.61

Moleculin Biotech, Inc. (MBRX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.83 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.0% since its last earnings release on August 13, 2026.

Moleculin Biotech Beat Consensus Estimates
Friday, August 14, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 8:30 AM ET
Earnings Whisper
-
vs ($0.83)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.61

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.

Sector

Healthcare

Industry

Biotechnology